CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience.
Frerichs KA et al.Expert Rev Clin Immunol. 2018 Feb 21. doi: 10.1080/1744666X.2018.1443809. [Epub ahead of print].

Multinucleated giant myeloma cells after failure of daratumumab therapy.
Guijarro F et al. Br J Haematol. 2018 Feb 22. doi: 10.1111/bjh.15139. [Epub ahead of print].

Defining a set of standardised outcome measures for newly diagnosed patients with multiple myeloma using the Delphi consensus method: the IMPORTA project.
Blade J et al. BMJ Open. 2018 Feb 22;8(2):e018850. doi: 10.1136/bmjopen-2017-018850.

Bayesian statistical models to estimate EQ-5D utility scores from EORTC QLQ data in myeloma. 
Kharroubi SA et al. Pharm Stat. 2018 Feb 20. doi: 10.1002/pst.1853. [Epub ahead of print].

Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.
Tarín-Arzaga L et al. Cancer. 2018 Feb 20. doi: 10.1002/cncr.31305. [Epub ahead of print].

Healthcare resource utilisation associated with skeletal-related events in European patients with multiple myeloma: results from a prospective, multinational, observational study.
Ashcroft J et al. Eur J Haematol. 2018 Feb 14. doi: 10.1111/ejh.13044. [Epub ahead of print].

Stem cell mobilization kinetics in elderly patients with multiple myeloma.
Dogu MH et al. Transfus Apher Sci. 2018 Feb 1. pii: S1473-0502(18)30018-1. doi: 10.1016/j.transci.2018.01.010. [Epub ahead of print].

Use of split peripheral blood stem cell harvests in myeloma identifies functional preservation of progenitor cells cryopreserved for several years and demonstrates no functional damage to the bone marrow microenvironment.
Watts MJ et al. Bone Marrow Transplant. 2018 Feb 12. doi: 10.1038/s41409-018-0121-9. [Epub ahead of print] No abstract available.

Undertreatment of Older Patients With Newly Diagnosed Multiple Myeloma in the Era of Novel Therapies.
Fakhri B et al. Clin Lymphoma Myeloma Leuk. 2018 Jan 31. pii: S2152-2650(17)31493-3. doi: 10.1016/j.clml.2018.01.005. [Epub ahead of print].

Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma.

Gupta S et al. Clin Lymphoma Myeloma Leuk. 2018 Jan 31. pii: S2152-2650(17)31411-8. doi: 10.1016/j.clml.2018.01.006. [Epub ahead of print].

Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy.
Snozek CLH et al. J Clin Apher. 2018 Feb 10. doi: 10.1002/jca.21619. [Epub ahead of print].

The multiple myeloma treatment landscape: international guideline recommendations and clinical practice in Europe.
Cavo M et al. Expert Rev Hematol. 2018 Feb 8. doi: 10.1080/17474086.2018.1437345. [Epub ahead of print].

Trends of incidence, mortality, and survival of multiple myeloma in Switzerland between 1994 and 2013.
Andres M et al. Cancer Epidemiol. 2018 Feb 5;53:105-110. doi: 10.1016/j.canep.2018.01.015. [Epub ahead of print].

Young female patients with multiple myeloma have low occurrence of osteolytic lesion.
Zhang D et al. Bone. 2018 Feb 3;110:21-28. doi: 10.1016/j.bone.2018.01.021. [Epub ahead of print].

Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop.
Tan D et al. Leuk Lymphoma. 2018 Feb 2:1-13. doi: 10.1080/10428194.2018.1427858. [Epub ahead of print].

Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H et al. Intern Med J. 2018 Feb;48(2):210-220. doi: 10.1111/imj.13707.